Form 4: Vericel Corp Director Exercises Options and Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
A Vericel Corp director, Kevin McLaughlin, exercised stock options and sold shares on November 13, 2024, under a pre-arranged 10b5-1 trading plan.
Summary
- Kevin McLaughlin, a director at Vericel Corp, executed transactions involving the company's stock on November 13, 2024.
- He exercised stock options to acquire 7,000 shares at a price of $3.74 per share.
- Concurrently, he sold 7,000 shares at a price of $55.54 per share.
- These transactions were conducted under a pre-established Rule 10b5-1 trading plan adopted on March 11, 2024.
- Following these transactions, McLaughlin directly owns 11,900 shares of Vericel Corp stock and 6,000 stock options.
Sentiment
Score: 5
Explanation: The document is a routine SEC filing detailing stock transactions by a company director. It doesn't indicate any positive or negative sentiment, it is a neutral event.
Industry Context
This is a standard SEC Form 4 filing, which is common for corporate insiders who trade company stock. The use of a 10b5-1 plan is a common practice to avoid accusations of insider trading.
Comparison to Industry Standards
- The use of a 10b5-1 trading plan is a common practice among corporate insiders at publicly traded companies like Vericel Corp, including companies such as Amgen, Biogen, and Regeneron.
- These plans allow insiders to sell shares at predetermined times and prices, mitigating the risk of insider trading allegations.
- The reported transactions are typical for directors who receive stock options as part of their compensation.
Stakeholder Impact
- The transactions may have a minor impact on the stock price, but the pre-planned nature of the trades under the 10b5-1 plan reduces the likelihood of significant market reaction.
- Shareholders may view the transactions as a normal part of executive compensation and stock ownership.
Key Dates
| Date | Description |
|---|---|
| 2015-03-20 | Stock options were originally granted. |
| 2024-03-11 | The 10b5-1 trading plan was adopted. |
| 2024-11-13 | Date of the stock option exercise and share sale. |
| 2024-11-15 | Date the Form 4 was signed. |
| 2025-03-20 | Stock options would otherwise expire. |
Keywords
Vericel Corp, stock options, insider trading, Form 4, Rule 10b5-1, equity securities, director, stock sale
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.